Cargando…

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

BACKGROUND & AIMS: Bile acids (BAs) are major regulators of hepatic BA and lipid metabolism but their mechanisms of action in non-alcoholic fatty liver disease (NAFLD) are still poorly understood. Here we aimed to explore the molecular and biochemical mechanisms of ursodeoxycholic acid (UDCA) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Michaela, Thorell, Anders, Claudel, Thierry, Jha, Pooja, Koefeler, Harald, Lackner, Carolin, Hoesel, Bastian, Fauler, Guenter, Stojakovic, Tatjana, Einarsson, Curt, Marschall, Hanns-Ulrich, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451470/ https://www.ncbi.nlm.nih.gov/pubmed/25617503 http://dx.doi.org/10.1016/j.jhep.2014.12.034

Ejemplares similares

Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients
por: Mueller, Michaela, et al.
Publicado: (2017)

The Reversed Feto-Maternal Bile Acid Gradient in Intrahepatic Cholestasis of Pregnancy Is Corrected by Ursodeoxycholic Acid
por: Geenes, Victoria, et al.
Publicado: (2014)

Influence of the Bile Acid Transporter Genes ABCB4, ABCB8, and ABCB11 and the Farnesoid X Receptor on the Response to Ursodeoxycholic Acid in Patients with Nonalcoholic Steatohepatitis
por: Kreimeyer, Henriette, et al.
Publicado: (2023)

Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy
por: Ovadia, Caroline, et al.
Publicado: (2020)

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

Bile acid transporters and regulatory nuclear receptors in the liver and beyond
por: Halilbasic, Emina, et al.
Publicado: (2013)

Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart
por: Hanafi, Noorul Izzati, et al.
Publicado: (2018)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice
por: Winston, Jenessa A., et al.
Publicado: (2021)

Strong activation of bile acid-sensitive ion channel (BASIC) by ursodeoxycholic acid
por: Wiemuth, Dominik, et al.
Publicado: (2013)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

Ursodeoxycholic Acid Alters Bile Acid and Fatty Acid Profiles in a Mouse Model of Diet-Induced Obesity
por: Zhang, Yunjing, et al.
Publicado: (2019)

The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis
por: Lajczak‐McGinley, Natalia K., et al.
Publicado: (2020)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
por: Manna, LB, et al.
Publicado: (2019)

Serum Bile Acids in Repaired Tetralogy of Fallot: A Marker for Liver and Heart?
por: Grangl, Gernot, et al.
Publicado: (2015)

Dihydroartemisinin-Ursodeoxycholic Bile Acid Hybrids in the Fight against SARS-CoV-2
por: Marchesi, Elena, et al.
Publicado: (2023)

Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile Acids
por: Xia, Yunlong, et al.
Publicado: (2022)

Ursodeoxycholic acid improves feto-placental and offspring metabolic outcomes in hypercholanemic pregnancy
por: Borges Manna, Luiza, et al.
Publicado: (2020)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk
por: Šimják, Patrik, et al.
Publicado: (2022)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo
por: Hassan, Haider M., et al.
Publicado: (2022)

Biological synthesis of ursodeoxycholic acid
por: Song, Peng, et al.
Publicado: (2023)

Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis
por: Chung, Jihwa, et al.
Publicado: (2016)

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis
por: Sombetzki, Martina, et al.
Publicado: (2015)

Successful treatment of an infant with congenital bile acid synthesis disorder type 3 by ursodeoxycholic acid: a case report
por: Mo, Weiqian, et al.
Publicado: (2022)

Circulating bile acids predict outcome in critically ill patients
por: Horvatits, Thomas, et al.
Publicado: (2017)

Effect of Ursodeoxycholic Acid Alone and Ursodeoxycholic Acid Plus Domperidone on Radiolucent Gallstones and Gallbladder Contractility in Humans
por: Tuncer, Ilyas, et al.
Publicado: (2012)

Bile Acids Induce Cdx2 Expression Through the Farnesoid X Receptor in Gastric Epithelial Cells
por: Xu, Yingji, et al.
Publicado: (2010)

Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis
por: van Schaik, Fiona D. M., et al.
Publicado: (2012)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
por: Kim, Sun-Gi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_83gfa7lmpf5db2rp4m761q9efr